Literature DB >> 7968278

Alterations in intrahepatic expression of duck hepatitis B viral markers with ganciclovir chemotherapy.

C Luscombe1, J Pedersen, S Bowden, S Locarnini.   

Abstract

Ducks congenitally infected with duck hepatitis B virus (DHBV) were treated with the guanosine analogue, ganciclovir, and the effect on serum and intrahepatic expression of DHBV DNA and viral proteins was examined. After 21 days of ganciclovir treatment, a substantial reduction in viraemia occurred; in contrast, the level of circulating DHBV surface antigen was unchanged. Ganciclovir therapy also substantially reduced the level of DHBV DNA replicative intermediates and the expression of viral core and surface antigen in hepatocytes. However, despite the antiviral treatment some liver cells, including the bile duct epithelial cells and putative oval cells, maintained their intense staining for the viral proteins. Furthermore, DHBV-infected cells in extrahepatic sites such as the pancreas, kidney and spleen were also unaffected by ganciclovir treatment. These results suggest that monotherapy with nucleoside analogues is unlikely to eliminate chronic hepadnaviral infection, and antiviral programs should be designed to target all cell populations infected by the virus.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7968278     DOI: 10.1111/j.1600-0676.1994.tb00072.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  9 in total

1.  Duck hepatitis B virus replication in primary bile duct epithelial cells.

Authors:  J Y Lee; J G Culvenor; P Angus; R Smallwood; A Nicoll; S Locarnini
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Inhibition of duck hepatitis B virus DNA replication by antiviral chemotherapy with ganciclovir-nalidixic acid.

Authors:  Y Wang; C Luscombe; S Bowden; T Shaw; S Locarnini
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

3.  Interaction between ganciclovir and foscarnet as inhibitors of duck hepatitis B virus replication in vitro.

Authors:  G Civitico; T Shaw; S Locarnini
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

4.  Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks.

Authors:  I Fourel; J M Cullen; J Saputelli; C E Aldrich; P Schaffer; D R Averett; J Pugh; W S Mason
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

5.  Inhibition of duck hepatitis B virus replication by 9-(2-phosphonylmethoxyethyl)adenine, an acyclic phosphonate nucleoside analogue.

Authors:  A J Nicoll; D L Colledge; J J Toole; P W Angus; R A Smallwood; S A Locarnini
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

6.  Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo.

Authors:  E Lin; C Luscombe; D Colledge; Y Y Wang; S Locarnini
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

7.  The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo.

Authors:  E Lin; C Luscombe; Y Y Wang; T Shaw; S Locarnini
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

8.  Association of different types of liver disease with demographic and clinical factors.

Authors:  Kao-Chi Cheng; Wen-Yuan Lin; Chiu-Shong Liu; Cheng-Chieh Lin; Hsueh-Chou Lai; Shih-Wei Lai
Journal:  Biomedicine (Taipei)       Date:  2016-08-13

9.  The Inaugural Australian Centre for Hepatitis Virology Public Panel Discussion on Viral Hepatitis Research-Lessons in Scientific Community Outreach.

Authors:  Thomas Tu; Chaturaka Rodrigo; Simone I Strasser; D Scott Bowden; Jennifer H MacLachlan; Heidi E Drummer
Journal:  Viruses       Date:  2021-09-15       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.